{"disease":{"id":"hemophilia-b-without-inhibitor","name":"hemophilia b without inhibitor"},"drugs":{"marketed":[{"drug_id":"hympavzi","indication_name":"Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia B (congenital factor IX deficiency) without factor IX inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hympavzi","generic_name":"Marstacimab-Hncq","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Tissue Factor Pathway Inhibitor (TFPI) Kunitz domain 2 (K2)","drug_class":"Tissue Factor Pathway Inhibitor (TFPI) Antagonist","quality_score":65,"revenue":null,"mechanism":"Monoclonal antibody against TFPI Kunitz domain 2 to neutralize TFPI and enhance coagulation."},{"drug_id":"concizumab","indication_name":"hemophilia B (congenital factor IX deficiency) with or without FIX inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alhemo","generic_name":"CONCIZUMAB","company_name":"Novo Nordisk Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Tissue Factor Pathway Inhibitor Antagonist [EPC]","quality_score":52,"revenue":null,"mechanism":"Alhemo works by blocking the activation of blood clotting factors to prevent excessive bleeding in people with hemophilia."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03619863","title":"ATHN 7: Hemophilia Natural History Study","phase":"","overall_status":"COMPLETED","enrollment_count":395,"lead_sponsor_name":"American Thrombosis and Hemostasis Network","has_results":false},{"nct_id":"NCT03818529","title":"ATHN 8: Previously Untreated Patients (PUPs) Matter Study","phase":"","overall_status":"COMPLETED","enrollment_count":237,"lead_sponsor_name":"American Thrombosis and Hemostasis Network","has_results":false},{"nct_id":"NCT06569108","title":"Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":125,"lead_sponsor_name":"Suzhou Alphamab Co., Ltd.","has_results":false},{"nct_id":"NCT04072237","title":"Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Catalyst Biosciences","has_results":true},{"nct_id":"NCT06125756","title":"Safety and Efficacy Clinical Study of Severe Hemophilia B Treatment With KL001","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":9,"lead_sponsor_name":"Affiliated Hospital of Guangdong Medical University","has_results":false},{"nct_id":"NCT06119659","title":"Safety and Efficacy Clinical Study of Severe Hemophilia B Treatment With KL001","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":9,"lead_sponsor_name":"Zhejiang University","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}